Cargando…

Designed, Synthetically Accessible Bryostatin Analogues Potently Induce Activation of Latent HIV Reservoirs in vitro

Bryostatin is a unique lead in the development of potentially transformative therapies for cancer, Alzheimer’s disease, and the eradication of HIV/AIDS. However, the clinical use of bryostatin has been hampered by its limited supply, difficulties in accessing clinically-relevant derivatives, and sid...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeChristopher, Brian A., Loy, Brian A., Marsden, Matthew D., Schrier, Adam J., Zack, Jerome A., Wender, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428736/ https://www.ncbi.nlm.nih.gov/pubmed/22914190 http://dx.doi.org/10.1038/nchem.1395

Ejemplares similares

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication
por: Marsden, Matthew D., et al.
Publicado: (2017)

Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016)

“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012)

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
por: Albert, Brice J., et al.
Publicado: (2017)

Activation of Latent HIV Using Drug-Loaded Nanoparticles
por: Kovochich, Michael, et al.
Publicado: (2011)

Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
por: Martínez-Bonet, Marta, et al.
Publicado: (2015)

Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold
por: Wender, Paul A., et al.
Publicado: (2014)

Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo
por: Pache, Lars, et al.
Publicado: (2020)

Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs
por: Wender, Paul A., et al.
Publicado: (2014)

Tracking HIV Rebound following Latency Reversal Using Barcoded HIV
por: Marsden, Matthew D., et al.
Publicado: (2020)

The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022)

Synthesis of a des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core
por: Kraft, Matthew B., et al.
Publicado: (2014)

Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012)

Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism
por: Díaz, Laura, et al.
Publicado: (2015)

Munc13 Is a Molecular Target of Bryostatin 1
por: Blanco, Francisco A., et al.
Publicado: (2019)

Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy
por: Rong, Libin, et al.
Publicado: (2009)

Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
por: Mehla, Rajeev, et al.
Publicado: (2010)

Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials
por: Nelson, Thomas J., et al.
Publicado: (2017)

Synthesis of seco-B-Ring Bryostatin Analogue WN-1 via C–C Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties
por: Andrews, Ian P., et al.
Publicado: (2014)

Heterogeneity of HIV-1 latent reservoirs
por: Zhao, Jia-Cong, et al.
Publicado: (2020)

Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal
por: Moran, Jose A., et al.
Publicado: (2023)

Establishment and stability of the latent HIV-1 DNA reservoir
por: Brodin, Johanna, et al.
Publicado: (2016)

Bryostatin-1: a promising compound for neurological disorders
por: Tian, Zhen, et al.
Publicado: (2023)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
por: Kim, Jocelyn T., et al.
Publicado: (2022)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

HIV-1 latent reservoir: size matters
por: Hodel, Flavia, et al.
Publicado: (2016)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

Measuring the size and decay dynamics of the HIV-1 latent reservoir
por: Liu, Runxia, et al.
Publicado: (2021)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

The latent HIV reservoir: current advances in genetic sequencing approaches
por: Moar, Preeti, et al.
Publicado: (2023)

Monocyte-derived macrophages contain persistent latent HIV reservoirs
por: Veenhuis, Rebecca T., et al.
Publicado: (2023)

Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline
por: Choi, Peter J., et al.
Publicado: (2020)

The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir
por: Benner, Sarah E., et al.
Publicado: (2022)

Mining for humoral correlates of HIV control and latent reservoir size
por: Das, Jishnu, et al.
Publicado: (2020)

The HIV-1 latent reservoir is largely sensitive to circulating T cells
por: Warren, Joanna A, et al.
Publicado: (2020)

Homeostatic proliferation of memory T cells and expansion of the HIV-1 latent reservoir
por: Bosque, A, et al.
Publicado: (2010)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Effect of the Latent Reservoir on the Evolution of HIV at the Within- and Between-Host Levels
por: Doekes, Hilje M., et al.
Publicado: (2017)

A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
por: Prendiville, J., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_3v9g0vosibrmssoqrkadh03ef0